HBx公司
生物
肝细胞癌
癌症研究
细胞生长
基因
转录组
免疫印迹
癌变
基因表达
微阵列
RNA干扰
转染
遗传学
核糖核酸
作者
Kai Zhu,Wenwen Huang,Wenju Wang,Liwei Liao,Shuo Li,Songlin Yang,Jingyi Xu,Lin Li,Mingyao Meng,Yanhua Xie,Shan He,Weiwei Tang,Haodong Zhou,Luxin Liang,Hui Gao,Yiyi Zhao,Zongliu Hou,Jing Tan,Ruhong Li
出处
期刊:Gene
[Elsevier BV]
日期:2020-04-21
卷期号:749: 144679-144679
被引量:19
标识
DOI:10.1016/j.gene.2020.144679
摘要
BACKGROUND: Hepatocellular carcinoma is one of the most common cancers worldwide. HBV-related HCC has characteristics of faster progression and worse prognosis. Previous studies have confirmed that HBx protein plays numbers of important roles in development of HBV-HCC. However, the molecular mechanism of carcinogenicity of HBx is still not well documented. METHODS: Firstly, a HCC cell line over-expressing HBx was established and its function was verified. Subsequently, the differentially expressed genes were detected by transcriptome sequencing technology and use the Western Blot technology to detect the up-regulated genes in HBx overexpressed cells, and the functional correlation of the genes was analyzed. Finally, tissue microarray was used to correlate up-regulated gene with clinical follow-up data to verify correlation with clinical prognosis. RESULTS: Over-expression of HBx could promote cell proliferation, and over-expression of HBx could up-regulate the expression of S100A4 protein. ShRNA experiments showed that HBx promoted cell proliferation by upregulating the expression of S100A4. IFN-α2b can down-regulate the expression of S100A4 and inhibit the proliferation of HCC cells. The expression of S100A4 in cancer was significantly up-regulated compared with adjacent tissues, and was also significantly associated with tumors volume, the expression of PD-L1 and the survival time of patients with HCC. CONCLUSION: In general, S100A4 may be an effective therapeutic target for HBV-HCC. And the connection between S100A4 and HBV are not clear yet. This study may play a guiding role in the future clinical treatment of HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI